Investigational Drug Information for Emapunil
✉ Email this page to a colleague
What is the development status for investigational drug Emapunil?
Emapunil is an investigational drug.
There have been 3 clinical trials for Emapunil.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 24th 2014.
The most common disease conditions in clinical trials are Sclerosis, Multiple Sclerosis, and Neurodegenerative Diseases. The leading clinical trial sponsors are Imperial College London, National Institute of Mental Health (NIMH), and [disabled in preview].
Summary for Emapunil
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 1 (2014-06-24) |
| Vendors | 0 |
Recent Clinical Trials for Emapunil
| Title | Sponsor | Phase |
|---|---|---|
| Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target | Imperial College London | N/A |
| Specific PET Radioligand Binding to Translocator Protein | National Institute of Mental Health (NIMH) | Phase 1 |
| Reproducibility of the 11C-PBR28 PET Signal | Imperial College London | N/A |
Clinical Trial Summary for Emapunil
Top disease conditions for Emapunil
Top clinical trial sponsors for Emapunil
US Patents for Emapunil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
